Vepco Bio-Tech Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 15-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 15-11-2024
- Company Age 28 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.00 Cr
as on 15-11-2024
- Satisfied Charges ₹ 6.30 Cr
as on 15-11-2024
- Revenue -96.55%
(FY 2023)
- Profit -3772.03%
(FY 2023)
- Ebitda -105.91%
(FY 2023)
- Net Worth -40.27%
(FY 2023)
- Total Assets -13.02%
(FY 2023)
About Vepco Bio-Tech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹3.00 Cr. The company has closed loans amounting to ₹6.30 Cr, as per Ministry of Corporate Affairs (MCA) records.
Narendar Idula and Shekar Junna serve as directors at the Company.
- CIN/LLPIN
U01110TG1996PTC023688
- Company No.
023688
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Apr 1996
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Mahabub Nagar, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Vepco Bio-Tech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narendar Idula  | Director | 22-Jun-2020 | Current |
| Shekar Junna | Director | 22-Dec-2017 | Current |
Financial Performance of Vepco Bio-Tech.
Vepco Bio-Tech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 96.55% decrease. The company also saw a substantial fall in profitability, with a 3772.03% decrease in profit. The company's net worth observed a substantial decline by a decrease of 40.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vepco Bio-Tech?
In 2023, Vepco Bio-Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Junna Life Sciences Private LimitedActive 18 years 8 monthsNarendar Idula and Shekar Junna are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 24 Nov 2020 | ₹3.00 Cr | Open |
Union Bank Of India Creation Date: 29 Aug 2011 | ₹1.00 Cr | Satisfied |
Union Bank Of India Creation Date: 29 Sep 2005 | ₹1.00 M | Satisfied |
How Many Employees Work at Vepco Bio-Tech?
Unlock and access historical data on people associated with Vepco Bio-Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vepco Bio-Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vepco Bio-Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
